Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Glioblastoma cancer stem cell biology: Potential theranostic targets

Sharifzad, Farzaneh, Ghavami, Saeid, Verdi, Javad, Mardpour, Soura, Mollapour Sisakht, Mahsa, Azizi, Zahra, Taghikhani, Adeleh, Łos, Marek J., Fakharian, Esmail, Ebrahimi, Marzieh, Hamidieh, Amir Ali · 2019 · Drug Resistance Updates

Abstract

Glioblastoma multiforme (GBM) is among the most incurable cancers. GBMs survival rate has not markedly improved, despite new radical surgery protocols, the introduction of new anticancer drugs, new treatment protocols, and advances in radiation techniques. The low efficacy of therapy, and short interval between remission and recurrence, could be attributed to the resistance of a small fraction of tumorigenic cells to treatment. The existence and importance of cancer stem cells (CSCs) is perceived by some as controversial. Experimental evidences suggest that the presence of therapy-resistant glioblastoma stem cells (GSCs) could explain tumor recurrence and metastasis. Some scientists, including most of the authors of this review, believe that GSCs are the driving force behind GBM relapses, whereas others however, question the existence of GSCs. Evidence has accumulated indicating that non-tumorigenic cancer cells with high heterogeneity, could undergo reprogramming and become GSCs. Hence, targeting GSCs as the "root cells" initiating malignancy has been proposed to eradicate this devastating disease. Most standard treatments fail to completely eradicate GSCs, which can then cause the recurrence of the disease. To effectively target GSCs, a comprehensive understanding of the biology of GSCs as well as the mechanisms by which these cells survive during treatment and develop into new tumor, is urgently needed. Herein, we provide an overview of the molecular features of GSCs, and elaborate how to facilitate their detection and efficient targeting for therapeutic interventions. We also discuss GBM classifications based on the molecular stem cell subtypes with a focus on potential therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drup.2018.03.003

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 175

Metadata

Authors
Sharifzad, F., Ghavami, S., Verdi, J., Mardpour, S., Mollapour Sisakht, M., Azizi, Z., Taghikhani, A., Łos, M. J., Fakharian, E., Ebrahimi, M., & Hamidieh, A. A.
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2019-01
Volume
42
Pages
35-45
ISSN
1368-7646 (ISSN-L)
OpenAlex
W2920869071
Cited by
175
References
23
FWCI
12.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glioblastoma cancer stem cell biology: Potential theranostic targets. https://app.cochat.ai/papers/10.1016/j.drup.2018.03.003
The paper
Sharifzad, F., Ghavami, S., Verdi, J., Mardpour, S., Mollapour Sisakht, M., Azizi, Z., Taghikhani, A., Łos, M. J., Fakharian, E., Ebrahimi, M., & Hamidieh, A. A. (2019). Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2018.03.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.